Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | APAF1 | O14727 | 1/20 | 0.67 |
| ▸ | GRK2 | P25098 | 1/20 | 0.67 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | MIF | P14174 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986294 | 0.88 | SMN1; SMN2 (0.62) | POLBAPAF1GRK2APOBEC3GSMN1; SMN2 | |
| SCHEMBL7668426 | 0.83 | MIF (0.71) | POLBSMN1; SMN2ALDH1A1MAPK10CA1 | |
| SCHEMBL10388533 | 0.83 | POLB (0.53) | POLBAPAF1GRK2APOBEC3GSMN1; SMN2 | |
| SCHEMBL24517994 | 0.81 | POLB (0.74) | POLBAPAF1GRK2APOBEC3GSMN1; SMN2 | |
| SCHEMBL7451017 | 0.81 | POLB (0.73) | POLBAPAF1GRK2APOBEC3GSMN1; SMN2 | |
| SCHEMBL10388005 | 0.80 | POLB (0.72) | POLBAPAF1GRK2APOBEC3GSMN1; SMN2 | |
| SCHEMBL10388882 | 0.80 | POLB (1.00) | POLBAPAF1GRK2APOBEC3GSMN1; SMN2 | |
| SCHEMBL10388872 | 0.80 | POLB (0.72) | POLBAPAF1GRK2APOBEC3GSMN1; SMN2 | |
| SCHEMBL7214876 | 0.79 | MIF (0.71) | SMN1; SMN2ALDH1A1MAPK10ITGB3ITGA2B | |
| SCHEMBL7367279 | 0.79 | MIF (0.71) | SMN1; SMN2ALDH1A1MAPK10ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455560-B1 | SUBSTITUTED (1-((3-ISOXAZOLIN-5-YL)CARBONYL/METHYL) -4-PIPERIDINYL) ACETIC ACID FOR USE IN INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-6319937-B1 | INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR TREATMENT OF THROMBOEMBOLIC DISORDERS. | DUPONT PHARMACEUTICALS COMPANY | 2001-11-20 | — | — | US | disclosed |
| US-4906277-A | Isoxazoline derivatives and plant growth regulators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1990-03-06 | — | — | US | disclosed |
| US-4889551-A | Isoxazoline derivatives and plant growth regulators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1989-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | FGB, F2, F13B | POLB 3806/4885APAF1 194/4885GRK2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.